It makes me wonder about amyvid and the rejection they had from the Centers for Medicare & Medicaid Services for reimbursal last year. Are they the ones that are after Lympro since it will be cheaper and they believe it has a better chance for approval from CMS? the addition of Paul T and the connections to Lilly are interesting to say the least. With blood diagnostics popping up more and more I would think Lilly would want to jump on that asap seeing that amyvid has had some issues for reimbursement and it is about to become obsolete from a pricing standpoint.